Converting from face-to-face to postal follow-up and its effects on participant retention, response rates and errors: lessons from the EQUAL study in the UK.
Chronic kidney disease
Errors
Follow-up
Prospective cohort study
Response rates
Retention
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
11 02 2022
11 02 2022
Historique:
received:
26
01
2021
accepted:
28
10
2021
entrez:
12
2
2022
pubmed:
13
2
2022
medline:
19
2
2022
Statut:
epublish
Résumé
Prospective cohort studies are challenging to deliver, with one of the main difficulties lying in retention of participants. The need to socially distance during the COVID-19 pandemic has added to this challenge. The pre-COVID-19 adaptation of the European Quality (EQUAL) study in the UK to a remote form of follow-up for efficiency provides lessons for those who are considering changing their study design. The EQUAL study is an international prospective cohort study of patients ≥65 years of age with advanced chronic kidney disease. Initially, patients were invited to complete a questionnaire (SF-36, Dialysis Symptom Index and Renal Treatment Satisfaction Questionnaire) at research clinics every 3-6 months, known as "traditional follow-up" (TFU). In 2018, all living patients were invited to switch to "efficient follow-up" (EFU), which used an abbreviated questionnaire consisting of SF-12 and Dialysis Symptom Index. These were administered centrally by post. Response rates were calculated using returned questionnaires as a proportion of surviving invitees, and error rates presented as the average percentage of unanswered questions or unclear answers, of total questions in returned questionnaires. Response and error rates were calculated 6-monthly in TFU to allow comparisons with EFU. Of the 504 patients initially recruited, 236 were still alive at the time of conversion to EFU; 111 of these (47%) consented to the change in follow-up. In those who consented, median TFU was 34 months, ranging from 0 to 42 months. Their response rates fell steadily from 88% (98/111) at month 0 of TFU, to 20% (3/15) at month 42. The response rate for the first EFU questionnaire was 60% (59/99) of those alive from TFU. With this improvement in response rates, the first EFU also lowered errors to baseline levels seen in early follow-up, after having almost trebled throughout traditional follow-up. Overall, this study demonstrates that administration of shorter follow-up questionnaires by post rather than in person does not negatively impact patient response or error rates. These results may be reassuring for researchers who are trying to limit face-to-face contact with patients during the COVID-19 pandemic.
Sections du résumé
BACKGROUND
Prospective cohort studies are challenging to deliver, with one of the main difficulties lying in retention of participants. The need to socially distance during the COVID-19 pandemic has added to this challenge. The pre-COVID-19 adaptation of the European Quality (EQUAL) study in the UK to a remote form of follow-up for efficiency provides lessons for those who are considering changing their study design.
METHODS
The EQUAL study is an international prospective cohort study of patients ≥65 years of age with advanced chronic kidney disease. Initially, patients were invited to complete a questionnaire (SF-36, Dialysis Symptom Index and Renal Treatment Satisfaction Questionnaire) at research clinics every 3-6 months, known as "traditional follow-up" (TFU). In 2018, all living patients were invited to switch to "efficient follow-up" (EFU), which used an abbreviated questionnaire consisting of SF-12 and Dialysis Symptom Index. These were administered centrally by post. Response rates were calculated using returned questionnaires as a proportion of surviving invitees, and error rates presented as the average percentage of unanswered questions or unclear answers, of total questions in returned questionnaires. Response and error rates were calculated 6-monthly in TFU to allow comparisons with EFU.
RESULTS
Of the 504 patients initially recruited, 236 were still alive at the time of conversion to EFU; 111 of these (47%) consented to the change in follow-up. In those who consented, median TFU was 34 months, ranging from 0 to 42 months. Their response rates fell steadily from 88% (98/111) at month 0 of TFU, to 20% (3/15) at month 42. The response rate for the first EFU questionnaire was 60% (59/99) of those alive from TFU. With this improvement in response rates, the first EFU also lowered errors to baseline levels seen in early follow-up, after having almost trebled throughout traditional follow-up.
CONCLUSIONS
Overall, this study demonstrates that administration of shorter follow-up questionnaires by post rather than in person does not negatively impact patient response or error rates. These results may be reassuring for researchers who are trying to limit face-to-face contact with patients during the COVID-19 pandemic.
Identifiants
pubmed: 35148682
doi: 10.1186/s12874-021-01453-0
pii: 10.1186/s12874-021-01453-0
pmc: PMC8832416
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Informations de copyright
© 2021. The Author(s).
Références
Eur J Epidemiol. 2001;17(11):991-9
pubmed: 12380710
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Nephrol Dial Transplant. 2020 May 1;35(5):755-764
pubmed: 32240311
Can J Nurs Res. 2004 Sep;36(3):82-98
pubmed: 15551664
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1624-39
pubmed: 27342598
Nephrol Dial Transplant. 2019 Oct 1;34(10):1707-1715
pubmed: 29939304
Am J Kidney Dis. 2018 Jul;72(1):93-103
pubmed: 29289476
Mayo Clin Proc. 1999 Apr;74(4):330-8
pubmed: 10221460
Cochrane Database Syst Rev. 2009 Jul 08;(3):MR000008
pubmed: 19588449
Lancet. 2006 Apr 22;367(9519):1319-27
pubmed: 16631910
BMJ. 2001 Dec 15;323(7326):1403-7
pubmed: 11744565
Contemp Clin Trials. 2018 Mar;66:74-79
pubmed: 29330082
Nephrol Dial Transplant. 2019 Jul 1;34(7):1189-1196
pubmed: 29905848
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
JMIR Cancer. 2018 Dec 20;4(2):e11373
pubmed: 30573450
Health Qual Life Outcomes. 2018 Feb 13;16(1):34
pubmed: 29439718
BMJ. 2005 Oct 22;331(7522):942
pubmed: 16223793
NPJ Digit Med. 2020 Feb 17;3:21
pubmed: 32128451
JAMA. 2020 Jun 2;323(21):2135-2136
pubmed: 32211830
J Clin Epidemiol. 2005 Jan;58(1):13-9
pubmed: 15649666
J Pain Symptom Manage. 2004 Mar;27(3):226-40
pubmed: 15010101
BMC Med Res Methodol. 2012 Oct 29;12:164
pubmed: 23106792
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
BMC Med Res Methodol. 2014 Sep 09;14:104
pubmed: 25204467
Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii27-31
pubmed: 22764196
Am J Kidney Dis. 2005 Mar;45(3):572-9
pubmed: 15754280
JPEN J Parenter Enteral Nutr. 1987 Jan-Feb;11(1):8-13
pubmed: 3820522
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
JMIR Mhealth Uhealth. 2017 Nov 01;5(11):e168
pubmed: 29092810
N Engl J Med. 2004 Apr 1;350(14):1414-21
pubmed: 15070791